List
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: Lymphoma, Marginal Zone. 8 results shown below.
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
Complete title: Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients with Hematologic Malignancies
Principal Investigator: Andrew Cowan
Study Number: RG1005491
Phase: II
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Complete title: Hematopoietic Stem Cell Transplantation from Haploidentical Donors in Patients with Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
Principal Investigator: Filippo Milano
Study Number: RG1005742
Phase: II
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)
Complete title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Principal Investigator: Ryan Lynch
Study Number: 20161033
Phase: II/III
A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Complete title: An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses Of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Principal Investigator: Mazyar Shadman
Study Number: 9837
Phase: I
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies
Complete title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER 1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
Principal Investigator: Damian Green, MD
Study Number: 9847
Phase: II
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)
Complete title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (INHL)
Principal Investigator: David Maloney, MD, PhD
Study Number: 9876
Phase: II
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Complete title: A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of
Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin
Lymphomas
Principal Investigator: Ajay Gopal, MD
Study Number: RG1005774
Phase: I
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Complete title: A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Principal Investigator: Chaitra Ujjani
Study Number: RG1007169
Phase: I/II